Pharma Stocks Hit by Trump’s Tariffs: Pharmaceutical Stocks Declined sharply by up to 5% on Friday, September 26, Following Us President Donald Trump ‘ Branded and Patent-Protected Medicines.Sun Pharma Experienced The Steepest Decline, Touching Its Yearly low at Rs 1,547, showing a 5% reduction from its last closing price. Biocon witnessed a 3.3% fall to Rs 344, whilst zydus lifescienes declined by 2.8%, settling at Rs 990.Aurobindo pharma decreased by 2.4% to Rs 1,070, and Dr. Reddy’s registered a 2.3% decline to Rs 1,245.30. Both Lupin and Cipla Saw A 2% Reduction, Ending at Rs 1,923.30 and Rs 1,480, Respected. Torrent pharma showed the smallest decline of 1.5%, Reaching Rs 3,480.65.At Approximately 9:30 AM, The Nifty Pharma Index Showed A Reduction of 2.54%.
Trump Tariff Uncertainteies loom
As per the announsement on truth social platform, trump declared that from October 1, all important branded or patented Medicines to the united States would face a 100% tariff, UNLESS Maanufaccators Production facilites within the country.Several Prominent Indian Pharmaceutical Firms, Including Sun Pharma, Dr. Reddy’s Laboratories, Cipla, Lupin, Aurobindo Pharma, and Zydus Lifescienes, MainTain Substantiial Export Operations to the Usa.Additional pharmaceutical entities such as syngene, gland pharma, biocon, and piramal pharma also generate considerable revaneue from the american market, particularly theround Medications, and biosimilars.The announsement specifies that exemptions would be granted soly to companies This policy aims to strengthen domestic production with reducing dependence on International sources for Premium, Patent-Protected Medications.“There will, therefore, be no tariff on these pharmaceutical products if construction has started,” The post Clarified, Defining “is Building” is Building “as Having Commented Physical Construction or Site Development.The Declaration is likely to affect Indian Pharmaceutical Companies that presented due to their branded medicines abroad for the American market. Share Prisis of Businesses with Substantial Us Export Presence Will Be Under Close observation, AlongSide Domestic Medicine Productions Who Cold Gain of Possible Alterations in Under Networks.
